New crown jewel valuing patient data

Send us Fan MailFor decades, biotech M&A followed a familiar script. Patents drove value. Molecules closed deals.That script is breaking.In today’s precision medicine transactions, the real asset is data. Longitudinal patient records, real-world evidence, and genomic datasets are now central to valuation. But unlike traditional IP, data comes with strings attached. Privacy laws, patient consent, and transfer restrictions can quietly determine whether that data is an asset or a liability.In this episode of KLF Deep Dive, we explore why clinical data is being treated as the new IP in biotech M&A, how weak consent frameworks can destroy deal value, and what acquirers should be asking during diligence before it’s too late.If you work in biotech, pharma, corporate development, or private equity, this episode breaks down a risk that is reshaping how deals get priced and structured.Listen in, and reach out if this issue is sitting inside one of your transactions.Episode HighlightsWhy patents alone no longer drive biotech valuationsHow precision medicine changed the M&A playbookClinical data as a regulated assetPatient consent and data transfer risksWhen valuable datasets become compliance liabilitiesWhat smart buyers are doing differently in diligenceSupport the showwww.kulkarnilawfirm.com